# US 2015/0307554 A1 · Nts-polyplex nanoparticles system for gene therapy of cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0307554 A1
- Document ID: US20150307554A1
- Status: Published application
- Kind: A1
- Application number: 13/984,548
- Filed: 2012-02-10
- Published: 2015-10-29
- Earliest claimed: 2011-02-10
- Inventors: Rosa Angelica CASTILLO RODRIGUEZ
- Web page: https://patentgrep.com/patent/US20150307554A1

## CPC

- C07K 7/083: {Neurotensin}
- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 47/62: the modifying agent being a protein, peptide or polyamino acid
- A61K 47/645: {Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT}
- A61K 47/6929: {the form being a nanoparticle, e.g. an immuno-nanoparticle}
- A61K 48/0025: {wherein the non-active part clearly interacts with the delivered nucleic acid}
- A61K 48/0091: {Purification or manufacturing processes for gene therapy compositions}
- C12N 9/1211: {Thymidine kinase (2.7.1.21)}
- C12N 15/87: Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12Y 207/01021: Thymidine kinase (2.7.1.21)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C07K 2319/035: containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The present invention describes a system of gene carrier nanoparticles capable of specifically internalize into cancer cells, eg, cancer cells involved in breast cancer, in vitro and in vivo. The system described allows the introduction of therapeutic genes specifically into target cells through NSTR1 receptor-mediated endocytosis of said system, making it possible to provide treatment for this type of conditions, for example by systemic, intravenous, or in situ administration.

## Claims

### Claim 1

A NTS-polyplex molecular complex, capable of transferring genes in vitro or in vivo into breast cancer cells that have NTSR1 receptor on their surface through its receptor-mediated endocytosis, characterized because comprise:
a) A plasmid carrying the gene to be transfected into cancer cells;
b) A caryophillic peptide electrostatically binded to a);
c) Poly-L-lysine also electrostatically binded to a);
d) Neurotensin chemically coupled to poly-L-lysine;
e) At least one fusogenic peptide chemically coupled to poly-L-lysine; and
f) Alternatively includes a tissue-specific transcriptional promoter.

### Claim 2 (depends on 1)

The molecular complex NTS-polyplex of claim 1, wherein the plasmid being transferred carries a suicide gene, which is transfected into cancer cells.

### Claim 3 (depends on 2)

The molecular complex NTS-polyplex of claim 2, wherein the suicide gene encodes HSV-Tk enzyme.

### Claim 4 (depends on 1)

The molecular complex NTS-polyplex of claim 1, wherein the plasmid being transferred carries a suicide gene, which is an apoptosis inductor protein activating other downstream proteins such as GSK3, Bax/Bc12, Bac/Bc12, or caspases.

### Claim 5 (depends on 1, 2, 3)

The molecular complex NTS-polyplex of claims 1 to 3, wherein the gene being transfected is regulated by the synthetic promoter of beta-catenin.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The molecular complex of claims 1 to 5, wherein the poly-L-lysine can be of varying molecular weight and being in its isomeric form L or D.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The use of a molecular complex of claims 1 to 6, for obtaining a medicament for treating breast cancer or cancers expressing functional NTSR1 receptor such as mesothelioma, colon cancer, lung cancer, pancreatic cancer, prostate cancer, or Ewing's sarcoma.

### Claim 8 (depends on 7)

The use of the NTS-polyplex molecular complex according to claim 7, wherein the medicament is for treating breast ductal adenocarcinoma, pre-invasive or invasive, either to prevent or treat metastatic events.

### Claim 9 (depends on 7, 8)

The use of the NTS-polyplex molecular complex according to claim 7 or 8, wherein the medicament is administered in conjunction with a prodrug substance, such as GCV, following a chemotherapy protocol specially designed, in therapeutically effective doses at particular times.

### Claim 10 (depends on 7, 8, 9)

The use of the NTS-polyplex molecular complex according to claims 7 to 9, wherein the medicament is intended for systemic, intravenous, or in situ administration.

### Claim 11 (depends on 7, 8, 9, 10)

The use of the NTS-polyplex molecular complex to manufacture a drug for cancer according to claims 7 to 10, wherein the treatment can also comprise conventional radiotherapy and chemotherapy.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6)

The use of the molecular complex of one of the claims 1 to 6, to transfect in vitro cells having functional NTSR1.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6)

A pharmaceutical composition to treat cancer cells that have NTSR1 receptor on their surface, characterized because comprise the NTS-polyplex molecular complex of the claims 1 to 6 and an acceptable pharmaceutical vehicle.

### Claim 14 (depends on 2, 13)

The pharmaceutical composition of the claim 13, characterized because comprise the NTS-polyplex molecular complex of the claim 2.

### Claim 15 (depends on 3, 13)

The pharmaceutical composition of the claim 13, characterized because comprise the NTS-polyplex molecular complex of the claim 3.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6)

A method for treating breast cancer or cancers expressing functional NTSR1 receptor such as mesothelioma, colon cancer, lung cancer, pancreatic cancer, prostate cancer, or Ewing's sarcoma wherein the NTS-polyplex molecular complex of claims 1 to 6 is administered to a patient suffer this cancer.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the cancer is breast ductal adenocarcinoma, pre-invasive or invasive, either to prevent or treat metastatic events.

### Claim 18 (depends on 16, 17)

The method according to claim 16 or 17, wherein the NTS-polyplex molecular complex is administered in conjunction with a prodrug substance, such as GCV, following a chemotherapy protocol specially designed, in therapeutically effective doses at particular times.

### Claim 19 (depends on 16, 17, 18)

The method according to claims 16 to 18, wherein the NTS-polyplex molecular complex is administered by systemic, intravenous, or in situ via.

### Claim 20 (depends on 16, 17, 18, 19)

The method according to claims 16 to 19, wherein the treatment can also comprise conventional radiotherapy and chemotherapy.

### Claim 21 (depends on 13, 16, 17, 18, 19, 20)

The method according to claims 16 to 20, wherein the NTS-polyplex molecular complex is administered through the pharmaceutical composition of the claim 13.

### Claim 22 (depends on 14, 16, 17, 18, 19, 20)

The method according to claims 16 to 20, wherein the NTS-polyplex molecular complex is administered through the pharmaceutical composition of the claim 14.

### Claim 23 (depends on 15, 16, 17, 18, 19, 20)

The method according to claims 16 to 20, wherein the NTS-polyplex molecular complex is administered through the pharmaceutical composition of the claim 15.
